The 17th Annual Scrip Awards, which will take place 2nd December 2021 at the Royal Lancaster, London, is now open for entries!
Since they began, the Scrip Awards has sought to applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its trophies span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising.
Over the past 17 years, the Scrip Awards has carved out a unique place in the industry calendar, with attendees coming from around the world to the prestigious ceremony and in the current climate it’s more important than ever to recognize what has been achieved.
Entry Deadline: 18 June, 2021
Awards Ceremony: 2 December, 2021
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 94 locations in 40 countries and has approximately 15,150 employees.
2021 sponsors include:
Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. With hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company's offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance and trial management. The company's thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations worldwide.
IQVIA™ is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward.
IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of Human Data Science a reality. IQVIA’s approach to Human Data Science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, advanced technology and analytics with extensive industry knowledge. To learn more, visit www.iqvia.com.
MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From MSD’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. In 2019 MSD had sales of more than $46 billion and we operate in more than 140 countries.
Parexel partners with life science and biopharmaceutical customers across the globe to help transform scientific discoveries into innovative new therapies that improve patient health. Our full-service offerings span early phase to post-marketing approval and include expert consultation across regulatory and consulting, laboratory services, real-world evidence, market access and more. With more than 35 years of experience, our therapeutic, technical and functional abilities are underpinned by a deep conviction In what we do best: supporting our customers in fulfilling the unmet medical needs of patients worldwide.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,600 collaborators from over 30 countries to improve the health of those in need – and to fulfill our dream that "every drug can be made and every disease can be treated."